Cannon Global Investment Management’s Contineum Therapeutics CTNM Stock Holding History

Cannon Global Investment Management’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$170K	Buy	+13,000	New	+$174K	0.33%	73

Other funds holding CTNM

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Cannon Global Investment Management's CTNM Position: Q1 2026 in Review

Cannon Global Investment Management opened a new position in Contineum Therapeutics (CTNM) in Q1 2026: 13,000 shares worth $170K. The stake represents 0.33% of the portfolio and ranks #73 among its holdings.

90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

Cannon Global Investment Management held 13,000 shares of Contineum Therapeutics worth $170K as of Q1 2026.
Contineum Therapeutics was a new Cannon Global Investment Management position in Q1 2026.
Contineum Therapeutics made up 0.33% of Cannon Global Investment Management's portfolio in Q1 2026, its #73 holding.
90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Cannon Global Investment Management's 13F filing for Q1 2026, filed 21 Apr 2026.